HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NBTY Shopping Has A Price As Charges Contribute To Earnings Drop

This article was originally published in The Tan Sheet

Executive Summary

NBTY net earnings fell 46% to $15.9 mil. in the fourth quarter, pulled down by a $4 mil. charge relating to the aborted acquisition of Twinlab, the company said Nov. 10

You may also be interested in...

NBTY ups shipments to GNC

NBTY is in the process of "dropping more new products into GNC" stores as the firm completes changes to the recently acquired Rexall MET-Rx sports nutrition brand product mix and labeling, Chairman & CEO Scott Rudolph says in Jan. 22 earnings call (1"The Tan Sheet" Nov. 17, 2003, p. 10). CFO Harvey Kamil adds that NBTY plans to double the run rate of its fast-selling low carb offerings - CarbWise and CarbSolutions - over the next 12 months. The vertically integrated supplement manufacturer reports a 60% increase in revenue to $385.1 mil. and a net income rise of 24% to $23.6 mil. in the first quarter ended Dec. 31. US Nutrition wholesale division leads NBTY business units with 142% sales growth to $179.2 mil., in part due to strong sales from Nature's Bounty, Osteo-Bi-Flex and Sundown brands...

Twinlab Sells Assets To IdeaSphere, Files For Protection From Creditors

IdeaSphere will acquire all assets of dietary supplement manufacturer Twinlab for $65 mil. following the company's filing for Chapter 11 bankruptcy

NBTY Aiming To Double Rexall Earnings; Closes Deal

NBTY plans to double newly acquired Rexall Sundown's earnings before interest, taxes, depreciation and amortization (EBITDA) to $78 mil. in the next nine months

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts